Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma
September 19th 2023An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.
Cross Q&A: Dosing Ponatinib in CML to Balance Efficacy and Cardiovascular Safety
September 19th 2023Experts discuss dosing strategies and risk factors for arterial occlusive events in ponatinib treatment for chronic myeloid leukemia, emphasizing the importance of balancing disease control and patient safety.
Biochemical and Clinical Progression: The Two Faces of Relapsed MM
September 12th 2023Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.